Clinical trial
Dose Ranging Study - Macroflux Parathyroid Hormone (PTH) in Postmenopausal Women…
NCT00489918 · Zosano Pharma Corporation, Industry · Completed
Key facts
| NCT number | NCT00489918 |
|---|---|
| Title | Dose Ranging Study - Macroflux Parathyroid Hormone (PTH) in Postmenopausal Women With Osteoporosis |
| Official title | A Dose Ranging Study of the Effects of Macroflux® PTH Compared With Macroflux® Placebo and FORTEO® in Postmenopausal Women With Osteoporosis |
| Lead sponsor | Zosano Pharma Corporation, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Osteoporosis |
| Intervention type | Drug |
| Interventions | teriparatide |
| Enrollment | 165 |
| Start date | Jun 1, 2007 |
| Primary completion | Apr 1, 2008 |
| Completion | Aug 1, 2008 |
| First posted | Jun 21, 2007 |
| Last update posted | Jul 31, 2018 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: